MOUNTAIN VIEW, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software and strategic services for optimizing clinical drug development, today announced that it has hired Jonathan Monteleone, M.S., and Herbert Struemper, Ph.D., as senior associate scientists in the Company’s Strategic Consulting Services group. Both Mr. Monteleone and Dr. Struemper will be based in the United States out of Pharsight’s Cary, North Carolina office.
“The addition of two new scientists is another key step as we continue to grow our world class consulting team at Pharsight,” said Shawn O’Connor, president, chief executive officer and chairman of Pharsight. “Dr. Struemper and Mr. Monteleone both have a unique combination of deep technical expertise and knowledge of drug development decision-making processes that will be of significant value to our consulting team. We look forward to their contributions that we believe will further enhance the services that we can provide to our clients.”
Dr. Struemper comes to Pharsight from Entelos Incorporated, where he led in silico research and development projects in rheumatoid arthritis, obesity and diabetes. He has broad experience in biomarker identification and evaluation, drug-disease modeling, and clinical trial design and simulation. Dr. Struemper holds a Ph.D. in Electrical Engineering from the University of Maryland in College Park. He also completed a postdoctoral research fellowship at the California Institute of Technology in Pasadena, California, where he designed motion control algorithms for nonlinear robotic systems. Dr. Struemper holds four life sciences patents, including two patents on methods for computer modeling of human physiological processes.
Mr. Monteleone joins Pharsight from Dov Pharmaceuticals, where he focused on population PK/PD modeling of small molecules in the areas of analgesia and depression. Mr. Monteleone also served as a lecturer in the Department of Pharmacology at the University of Auckland in New Zealand, where he provided instruction on clinical pharmacokinetics concepts and modeling tools, including Pharsight’s WinNonlin(R). Mr. Monteleone holds an M.S. in Toxicology from the University of Arizona and has completed coursework for his Ph.D. in Pharmacology and Clinical Pharmacology from the University of Auckland. Mr. Monteleone has authored or co-authored several original research articles in the area of clinical trial design and simulation-based design optimization.
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company’s goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight’s approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight(R) is a registered trademark of Pharsight Corporation. All other brand and product names are trademarks or registered trademarks of their respective holders.
Pharsight Corporation
CONTACT: Investors, Jennifer Beugelmans, +1-646-201-5447, or Doug Sherk,+1-415-896-6820, or Media, Jennifer Saunders, +1-646-201-5431, all of EVCGroup for Pharsight Corporation
Web site: http://www.pharsight.com/
